These data demonstrate: (i) [111In]PD-L1-mAb and NIR-PD-L1-mAb detect endogenous tumor PD-L1 expression, and (ii) in vivo specificity and dose dependent distribution of the anti-PD-L1 antibody. This evidence concerns the gene CD274 and neoplasm.